Abstract On April 4, 2019, the FDA approved a supplemental new drug application for
palbociclib (IBRANCE), to expand the approved indications in women with hormone …

Abstract On February 19, 2016, the FDA approved palbociclib (Ibrance, Pfizer) for use in
combination with fulvestrant (Faslodex, AstraZeneca) for the treatment of women with …

Purpose Real-world data are critical to demonstrate the reproducibility of evidence and
external generalizability of randomized clinical trials. Palbociclib is an oral small-molecule …

Abstract On February 3, 2015, the FDA granted accelerated approval to palbociclib
(IBRANCE, Pfizer Inc.), an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4 and CDK6) …

Background Palbociclib administered with endocrine therapy was tolerable when the overall
incidence of toxicities was assessed separately for three PALOMA studies. This study …

Palbociclib (Ibrance®) is an oral, reversible, selective, small-molecule inhibitor of cyclin-
dependent kinases (CDK) 4 and CDK6 developed by Pfizer for the treatment of cancer …

Background The activity of palbociclib as a single agent in advanced breast cancer has not
been extensively studied, with the only available clinical data limited to heavily pretreated …

Background. Palbociclib enhances endocrine therapy and improves clinical outcomes in
hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative …

Purpose Palbociclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor approved for
use in postmenopausal women with hormone receptor-positive, human epidermal growth …

Purpose Palbociclib is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, approved in
combination with endocrine therapy for the treatment of women and men with hormone …